Rheumatology · 2 h ago
Exploratory models predict short-term functional improvement in rheumatic diseases
A prospective observational study of 64 adults with varied rheumatic and musculoskeletal conditions assessed functional improvement after four weeks of routine individualized treatment. Models using baseline characteristics showed high apparent discrimination, but require validation before clinical use.
- Study included 64 adults with varied rheumatic and musculoskeletal diagnoses.
- Functional response was assessed after four weeks of routine treatment.
- Both models showed high apparent discrimination in the development cohort.
- Validation is required before clinical use.
Researchers followed 64 adults with heterogeneous rheumatic and musculoskeletal diagnoses from baseline through four weeks of individualized routine pharmacological treatment. They assessed clinically meaningful improvement using the Lower Extremity Functional Scale (LEFS; increase of at least 9 points) and the Disabilities of the Arm, Shoulder and Hand score (DASH; decrease of at least 12 points), then developed separate logistic regression models.
LEFS response occurred in 43 patients (67.2%) and DASH response in 35 (54.7%). Shorter disease duration, lower GAD-7 anxiety score and lower BMI were associated with response in both models. Higher total protein and lower baseline LEFS were additionally associated with LEFS response; higher hemoglobin was associated with DASH response. Apparent AUROCs were 0.928 for LEFS and 0.910 for DASH, with respective Brier scores of 0.100 and 0.111.
These findings suggest potential for baseline characteristics to support short-term prognostic stratification, but the models were developed in a small, diagnostically heterogeneous cohort and performance was not optimism-corrected. The authors describe the models as exploratory; internal and external validation are needed before clinical application. The study was funded through a grant from the National Research Foundation of Ukraine.
In practice
For adults with heterogeneous rheumatic and musculoskeletal diagnoses receiving routine individualized pharmacological treatment, baseline disease duration, GAD-7 score and BMI were associated with four-week LEFS and DASH improvement; additional associations differed by outcome. These are exploratory prognostic models from only 64 patients, with apparent performance measured in the development cohort and no optimism correction. The findings do not establish that using these factors improves treatment decisions, and internal and external validation are needed before clinical application.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Clinical Rheumatology: Short-term prognostic models for functional improvement in rheumatic diseases: an exploratory prospective study ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.